Wikipedia -WSS

Wikipedia

author：Wikipedia 2025-09-27 12:57:35 - browse：1

Two people run on the sugar-phosphate backbone of DNA while holding base pairs — in the lab coverage from STAT — Adobe

LONDON — Widespread genetic testing as well as the development of cutting-edge, customized genetic therapies have opened the door to treating many more inherited conditions than previously possible. A few recent cases, in which bespoke medicines were created for children with exceedingly rare mutations, have raised hopes for furthering the approach.

Now, researchers and government agencies in the U.K. are trying to figure out the nitty-gritty to replicate those early one-off successes for as many patients as possible — what sort of preclinical testing a tailor-made treatment needs to go through before being used, what regulatory thresholds each treatment needs to clear, and how to pay for these therapies.

“A lot of the barriers are no longer scientific — we can make these drugs,” said Matthew Wood, a professor of pediatrics at the University of Oxford. “It’s more about, can we make them at a cost that is reasonable enough? And can we get the regulators to reduce the barriers to doing this so that when a patient shows up, you can actually make a drug quickly enough to benefit that patient, rather than it costing huge amounts of money and taking two or three years to do it?”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New air purifier tech could be key to improving indoor air quality
Next article： STAT Virtual Event: The State of Biosimilars: What to Watch

focus

hotspot

WSS

Histogen: Failed biotech offers rare public look inside

Custom gene therapy hints at new path for rare disease treatments

Was Amgen transparent enough on FDA's concern on cancer drug?

FDA approves RSV monoclonal antibody for infants, toddlers

Stroke deaths set to near 10 million globally by 2050

FDA panel signals lack of confidence in Amgen cancer drug data

entertainment

Wikipedia

focus

How one medical school became remarkably diverse

Stroke deaths set to near 10 million globally by 2050

In age of alternative facts, a scholarly course on calling out crap

Eli Lilly buys Point Biopharma in radiopharmaceuticals play

Duchenne breakthrough therapy leaves behind pioneering families

Was Amgen transparent enough on FDA's concern on cancer drug?

The cancer drug shortage isn’t new — and neither are the solutions

Liquid biopsy for lung cancer is launched by Delfi

Activists slam private health insurers over coverage restrictions

At Orexo, a ‘turning point’ for everything but digital health

focus

Rescued Australian man who was adrift 3 months in Pacific with dog 'grateful' to be alive

Physician executives need more than on

Medicare has a new plan to address drug shortages

Readout Newsletter: Biotech news, including Moderna's Covid vaccine

In $4.8 billion deal, Bristol Myers Squibb to buy cancer player Mirati

Analysis of telehealth claims data suggest service duplication

entertainment

focus

hotspot

explore